150 related articles for article (PubMed ID: 6130768)
1. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193)--II. Relationship between dose level and biochemical effects in P388 leukemia in vivo.
Jayaram HN; Smith AL; Glazer RI; Johns DG; Cooney DA
Biochem Pharmacol; 1982 Dec; 31(23):3839-45. PubMed ID: 6130768
[TBL] [Abstract][Full Text] [Related]
2. Mechanism of resistance to the oncolytic C-nucleoside 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC-286193).
Jayaram HN; Cooney DA; Glazer RI; Dion RL; Johns DG
Biochem Pharmacol; 1982 Aug; 31(15):2557-60. PubMed ID: 7126269
[No Abstract] [Full Text] [Related]
3. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-beta-D-ribofuranosylthiazole-4-carboxamide (NSC 286193).
Jayaram HN; Dion RL; Glazer RI; Johns DG; Robins RK; Srivastava PC; Cooney DA
Biochem Pharmacol; 1982 Jul; 31(14):2371-80. PubMed ID: 6127085
[No Abstract] [Full Text] [Related]
4. The conversion of 2-beta-D-ribofuranosylthiazole-4-carboxamide to an analogue of NAD with potent IMP dehydrogenase-inhibitory properties.
Cooney DA; Jayaram HN; Gebeyehu G; Betts CR; Kelley JA; Marquez VE; Johns DG
Biochem Pharmacol; 1982 Jun; 31(11):2133-6. PubMed ID: 6126195
[No Abstract] [Full Text] [Related]
5. Studies on the mechanism of action of tiazofurin metabolism to an analog of NAD with potent IMP dehydrogenase-inhibitory activity.
Cooney DA; Jayaram HN; Glazer RI; Kelley JA; Marquez VE; Gebeyehu G; Van Cott AC; Zwelling LA; Johns DG
Adv Enzyme Regul; 1983; 21():271-303. PubMed ID: 6152729
[TBL] [Abstract][Full Text] [Related]
6. Studies on the mechanism of action of 2-beta-D-ribofuranosylthiazole-4-carboxamide--V. Factors governing the response of murine tumors to tiazofurin.
Ahluwalia GS; Jayaram HN; Plowman JP; Cooney DA; Johns DG
Biochem Pharmacol; 1984 Apr; 33(8):1195-203. PubMed ID: 6143562
[TBL] [Abstract][Full Text] [Related]
7. Studies on the mechanism of action of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide). VI. Biochemical and pharmacological studies on the degradation of thiazole-4-carboxamide adenine dinucleotide (TAD).
Ahluwalia GS; Cooney DA; Marquez VE; Jayaram HN; Johns DG
Biochem Pharmacol; 1986 Nov; 35(21):3783-90. PubMed ID: 2877671
[TBL] [Abstract][Full Text] [Related]
8. Alterations in glycoprotein synthesis and guanosine triphosphate levels associated with the differentiation of HL-60 leukemia cells produced by inhibitors of inosine 5'-phosphate dehydrogenase.
Sokoloski JA; Blair OC; Sartorelli AC
Cancer Res; 1986 May; 46(5):2314-9. PubMed ID: 2870796
[TBL] [Abstract][Full Text] [Related]
9. Eicar (5-ethynyl-1-beta-D-ribofuranosylimidazole-4-carboxamide). A novel potent inhibitor of inosinate dehydrogenase activity and guanylate biosynthesis.
Balzarini J; Karlsson A; Wang L; Bohman C; Horská K; Votruba I; Fridland A; Van Aerschot A; Herdewijn P; De Clercq E
J Biol Chem; 1993 Nov; 268(33):24591-8. PubMed ID: 7901217
[TBL] [Abstract][Full Text] [Related]
10. Effects of the inhibitors of IMP dehydrogenase, tiazofurin and mycophenolic acid, on glycoprotein metabolism.
Sokoloski JA; Sartorelli AC
Mol Pharmacol; 1985 Dec; 28(6):567-73. PubMed ID: 2867464
[TBL] [Abstract][Full Text] [Related]
11. Dehydrogenase binding by tiazofurin anabolites.
Goldstein BM; Bell JE; Marquez VE
J Med Chem; 1990 Apr; 33(4):1123-7. PubMed ID: 1969483
[TBL] [Abstract][Full Text] [Related]
12. Phase I evaluation and pharmacokinetics of tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide, NSC 286193).
Melink TJ; Von Hoff DD; Kuhn JG; Hersh MR; Sternson LA; Patton TF; Siegler R; Boldt DH; Clark GM
Cancer Res; 1985 Jun; 45(6):2859-65. PubMed ID: 3986813
[TBL] [Abstract][Full Text] [Related]
13. Biochemical differences among four inosinate dehydrogenase inhibitors, mycophenolic acid, ribavirin, tiazofurin, and selenazofurin, studied in mouse lymphoma cell culture.
Lee HJ; Pawlak K; Nguyen BT; Robins RK; Sadée W
Cancer Res; 1985 Nov; 45(11 Pt 1):5512-20. PubMed ID: 2865005
[TBL] [Abstract][Full Text] [Related]
14. Modulation of IMP dehydrogenase activity and guanylate metabolism by tiazofurin (2-beta-D-ribofuranosylthiazole-4-carboxamide).
Lui MS; Faderan MA; Liepnieks JJ; Natsumeda Y; Olah E; Jayaram HN; Weber G
J Biol Chem; 1984 Apr; 259(8):5078-82. PubMed ID: 6143752
[TBL] [Abstract][Full Text] [Related]
15. IMP dehydrogenase: inhibition by the anti-leukemic drug, tiazofurin.
Yamada Y; Natsumeda Y; Yamaji Y; Jayaram HN; Tricot GJ; Hoffman R; Weber G
Leuk Res; 1989; 13(2):179-84. PubMed ID: 2564451
[TBL] [Abstract][Full Text] [Related]
16. Comparative in vitro studies of Tiazofurin and a selenazole analog.
Streeter DG; Robins RK
Biochem Biophys Res Commun; 1983 Sep; 115(2):544-50. PubMed ID: 6138036
[TBL] [Abstract][Full Text] [Related]
17. Mechanism of resistance to tiazofurin in hepatoma 3924A.
Jayaram HN; Pillwein K; Lui MS; Faderan MA; Weber G
Biochem Pharmacol; 1986 Feb; 35(4):587-93. PubMed ID: 2868729
[TBL] [Abstract][Full Text] [Related]
18. Biochemical mechanisms of resistance to tiazofurin.
Jayaram HN
Adv Enzyme Regul; 1985; 24():67-89. PubMed ID: 3835825
[TBL] [Abstract][Full Text] [Related]
19. Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase.
Franchetti P; Cappellacci L; Grifantini M; Barzi A; Nocentini G; Yang H; O'Connor A; Jayaram HN; Carrell C; Goldstein BM
J Med Chem; 1995 Sep; 38(19):3829-37. PubMed ID: 7562914
[TBL] [Abstract][Full Text] [Related]
20. Targets and markers of selective action of tiazofurin.
Weber G; Natsumeda Y; Pillwein K
Adv Enzyme Regul; 1985; 24():45-65. PubMed ID: 2424286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
